Literature DB >> 12397571

Asthma, beta-agonists, and development of congestive heart failure: results of the ABCHF study.

David M Sengstock1, Omar Obeidat, Venkat Pasnoori, Pradeep Mehra, Keisha R Sandberg, Peter A McCullough.   

Abstract

BACKGROUND: Previous studies demonstrated an association between asthma and idiopathic dilated cardiomyopathy (IDCM), raising concerns regarding chronic beta-agonist inhaler use. The purpose of this investigation was to replicate that association. METHODS AND
RESULTS: We identified 67 patients with IDCM and 130 controls with predominately ischemic cardiomyopathy. Patients were administered a structured, detailed phone survey by blinded interviewers, and had chart abstractions performed. We had 80% power to detect an odds ratio (OR) > or = 2.6 for the relation of asthma and IDCM. A history of asthma was present in 19.4% v 12.3% for cases and controls respectively, OR, 1.72, (95% confidence interval [CI], 0.72, 4.09), P = .18. The duration of asthma was higher in cases: 32.3 (19.7) years v 13.8 (15.0) years (P = 0.007). With adjustment for confounders, multivariate analyses revealed no significant relations between asthma or beta-agonist use and the later development of IDCM.
CONCLUSIONS: It is unlikely that previously occurring asthma or beta-agonist use has a strong relationship to the development of IDCM; however, IDCM and atopic diseases may cluster in families, warranting further work into the genetic relations between atopy and IDCM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397571     DOI: 10.1054/jcaf.2002.127771

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  9 in total

Review 1.  β-Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives.

Authors:  Maria Gabriella Matera; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

Review 2.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

Review 3.  Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

Authors:  Vasiliki Petta; Fotis Perlikos; Stelios Loukides; Petros Bakakos; Athanasios Chalkias; Nicoletta Iacovidou; Theodoros Xanthos; Dorothea Tsekoura; Georgios Hillas
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 4.  More than just a T-box: the role of T-bet as a possible biomarker and therapeutic target in autoimmune diseases.

Authors:  Niannian Ji; Rebecca A Sosa; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2011-03       Impact factor: 4.196

Review 5.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.

Authors:  Shelley R Salpeter
Journal:  Drugs       Date:  2009-10-22       Impact factor: 9.546

8.  T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17.

Authors:  Manu Rangachari; Nora Mauermann; René R Marty; Stephan Dirnhofer; Michael O Kurrer; Vukoslav Komnenovic; Josef M Penninger; Urs Eriksson
Journal:  J Exp Med       Date:  2006-07-31       Impact factor: 14.307

Review 9.  Beta-blocker use and COPD mortality: a systematic review and meta-analysis.

Authors:  Mahyar Etminan; Siavash Jafari; Bruce Carleton; John Mark FitzGerald
Journal:  BMC Pulm Med       Date:  2012-09-04       Impact factor: 3.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.